Robert H. Christenson, PhD, University of Maryland, outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.
Does the testing reagent stockpile for COVID-19 impact other conditions? According to Robert H. Christenson, PhD, a professor at University of Maryland Medical School, not directly.
Many of the necessary components for mass testing are SARS-CoV-2 specific. This has led to a stockpiling of resources by various institutions, but has not impinged on the supply of reagents broadly.
In this segment, Dr. Christenson outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.
According to the US Centers for Disease Control and Prevention (CDC) the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel contains 4 reagents:
There are 3 primer-probe mixes for:
As well as a 4th noninfectious positive control material which yields a positive result in each assay included in the panel.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.